替格瑞洛对急性冠脉综合征冠脉多支病变行PCI术治疗效果的中期随访  

Midterm follow-up outcomes of Ticagrelor on acute coronary syndrome undergoing percutaneous coronary intervention

作　　者：刘浙波 夏豪[1] 方钊[1] 王建铭[1] 陶波[1] 杨洋[1] 李晶[1] 

机构地区：[1]武汉大学人民医院心内科,心血管病湖北省重点实验室,湖北省武汉市430060

出　　处：《中国心血管病研究》2016年第7期627-631,共5页Chinese Journal of Cardiovascular Research

基　　金：国家自然科学基金（项目编号：81270184）

摘　　要：目的 探讨替格瑞洛对急性冠脉综合征冠脉多支病变行PCI术治疗的有效性及安全性.方法 选取2013年8月至2015年8月入住我院的急性冠脉综合征多支病变患者226例为研究对象,并随机将患者分为替格瑞洛组（试验组,n=99,术前顿服180 mg,术后每次90 mg,每日2次）和氯吡格雷组（对照组,n=127,术前300 mg顿服,术后每次75 mg,每日1次）.术后均对患者随访6个月,比较两组患者基本临床资料、冠脉病变特征、药物使用情况及6个月内主要不良心血管事件、不良反应发生.结果 两组患者基本临床资料、冠脉病变特征、药物使用情况比较未见统计学差异（P＞0.05）,具有可比性.试验组患者随访期间（6个月内）MACE发生率显著低于对照组（5.1％比14.2％）,差异有统计学意义（P＜0.05）;呼吸困难发生率显著高于对照组（7.1％比1.6％）,差异有统计学意义;出血事件及总不良反应发生率两组比较未见统计学差异（P＞0.05）.结论 替格瑞洛对急性冠脉综合征冠脉多支病变行PCI术患者具有良好的有效性及安全性.Objective To evaluate the safety and efficacy of antiplatelet therapy of Ticagrelor on patients suffering from acute coronary syndrome with multivcssel disease undergoing percutaneous coronary intervention. Methods 226 of acute coronary syndrome with multivessel disease who received PCI were randomly divided into Ticagrclor group （n=99, preoperative 180 mg loading, 90 mg after operative, two times per day） and Clopidogrel group （n=127, preoperative 300 mg loading, 75 mg after operative, once per day）. The Basic clinical data, labo- ratory results, therapeutic of drugs, coronary artery disease characteristics and the major adverse cardiovascular events of the follow-up for 6 month and bleeding complications were observed and compared in the two group. Results The basic clinical data, laboratory results, therapeutic of drugs, coronary artery disease characteristics had no statistical significance between two group （P〉0.05）. Compared with control group the incidence of MACE was significantly lower than that of Clopidogrel group （5.1% vs 14.2%, P〈0.05） within 6 month, but the inci- dence of dispend was significantly higher than that of Clopidogrel group（7.1% vs. 1.6%, P〈0.05 ）. The two groups had no statistical significance in adverse reaction and bleeding complications （P〉0.05）. Conclusion Antiplatelet therapy of Ticagrelor on patients suffering from acute coronary syndrome with muhivessel disease undergoing percu- taneous coronary intervention has good efficacy and safety.

关 键 词：替格瑞洛 急性冠脉综合征 多支病变 经皮冠状动脉介入治疗 

分 类 号：R543.3[医药卫生—心血管疾病]